10-K: Rafael Holdings Reports Annual Results, Highlights Strategic Shift Towards Clinical Programs

Rafael Holdings' annual report details a strategic shift towards clinical-stage pharmaceutical investments, particularly focusing on the planned merger with Cyclo Therapeutics and its lead drug, Trappsol Cyclo.

Summary

• Rafael Holdings is transitioning its focus towards clinical-stage pharmaceutical companies, with a planned merger with Cyclo Therapeutics as a key priority.
• The company is curtailing early-stage development efforts, including pre-clinical research at Barer Institute, to reduce spending and explore strategic opportunities.
• Rafael Holdings' portfolio includes investments in LipoMedix, Barer, Cornerstone, Rafael Medical Devices, and Day Three Labs.
• The company sold its headquarters building in Newark, New Jersey in August 2022 for $49.4 million, retaining a portion of a commercial building in Jerusalem, Israel as its sole remaining real estate asset.
• As of November 5, 2024, Rafael Holdings had 28 full-time and 3 part-time employees.
• The aggregate market value of the voting and non-voting stock held by non-affiliates of the registrant was approximately $34.4 million as of January 31, 2024.
• As of November 5, 2024, there were 787,163 shares of Class A common stock and 23,886,987 shares of Class B common stock outstanding.
• The company has entered into a merger agreement with Cyclo Therapeutics, with the merger expected to close after approvals from both companies' stockholders and the effectiveness of a registration statement on Form S-4.
• The merger agreement values Cyclo shares at $0.95 per share and the company at its cash value combined with the value of its marketable securities and certain other investments less current liabilities.
• The company intends to fund Cyclo's Phase III clinical trial for Trappsol Cyclo to its interim analysis in mid-2025 and focus its efforts on Trappsol Cyclo as its lead clinical program.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there's a clear strategic shift towards clinical programs and a planned merger, the financial results are weak, and there are significant risks and uncertainties. The curtailment of early-stage research and the dependence on a single clinical program are also concerning.

Positives

• The company is strategically focusing on clinical-stage pharmaceutical investments, which may offer higher growth potential.
• The planned merger with Cyclo Therapeutics could provide a significant lead clinical program with Trappsol Cyclo.
• The sale of the headquarters building generated approximately $33 million in net proceeds.
• The company has a diverse portfolio of investments in pharmaceutical and medical device companies.

Negatives

• The company is curtailing early-stage development efforts, which may limit future pipeline opportunities.
• The company has a limited operating history, making it difficult to evaluate its business and prospects.
• The company may find it difficult to raise additional capital.
• The company is dependent on the success of Cyclo Therapeutics Phase III trial for Trappsol Cyclo.
• The company has limited control over third-party manufacturers and service providers.
• The company faces substantial competition in the biopharmaceutical and medical device industries.

Risks

• The company has limited resources and could find it difficult to raise additional capital.
• The company's future success depends significantly on the results of Cyclo Therapeutics Phase III trial for Trappsol Cyclo.
• Preclinical and clinical drug development is a lengthy and expensive process with an uncertain outcome.
• The company may not be able to consummate any investment, business combination or other transaction.
• The company is controlled by its principal stockholder, which limits the ability of other stockholders to affect the management of the company.
• The Exchange Ratio used in the Merger with Cyclo will be determined in accordance with a formula and is not yet knowable, and could be materially different than currently anticipated.
• The company relies significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cyber security incidents, could harm the company's ability to operate its business and that of the companies in which it holds interests effectively.

Future Outlook

The company intends to focus its efforts on making Trappsol Cyclo its lead clinical program upon closing of the planned merger with Cyclo, and will fund the TransportNPC phase III clinical trial to its interim analysis in the middle of 2025. The company will then make a determination as to whether or not to file an NDA for Trappsol Cyclo.

Management Comments

• The company resolved to curtail its early-stage development efforts, including pre-clinical research at Barer, to reduce spending as the Company focuses on exploring strategic opportunities.
• The Companys primary focus is to expand our investment portfolio through opportunistic and strategic investments including therapeutics, which address high unmet medical needs.

Industry Context

The announcement reflects a broader trend in the biopharmaceutical industry where companies are increasingly focusing on late-stage clinical assets with higher potential for near-term commercialization. The planned merger with Cyclo and the focus on Trappsol Cyclo align with this trend, as the company seeks to capitalize on a promising clinical program.

Comparison to Industry Standards

• The company's shift towards clinical-stage assets is similar to strategies employed by other biopharmaceutical companies seeking to de-risk their portfolios and focus on assets with a higher probability of regulatory approval.
• The company's decision to curtail early-stage research is a common practice among smaller biotechs that need to manage resources carefully and prioritize late-stage assets.
• The company's reliance on third-party manufacturers and service providers is a standard practice in the biopharmaceutical industry, particularly for smaller companies that lack the resources to build their own infrastructure.
• The company's focus on orphan drug designations and fast track approvals is a common strategy for companies developing treatments for rare diseases, as these designations can provide market exclusivity and expedited regulatory review.

Related Party Transactions

• The company leased space to related parties (including IDT Corporation) which represented approximately 17% and 42% of the Companys total revenue for the years ended July 31, 2024 and 2023, respectively.
• Howard S. Jonas, the company's Executive Chairman and Chairman of the Board, controls a majority of the voting power of the company's capital stock.
• The company has a relationship with RP Finance, an entity associated with members of the family of Howard Jonas, which holds a 37.5% equity interest in RP Finance.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital.
• Shareholders may benefit from the potential success of the Trappsol Cyclo program.
• Employees may be affected by the strategic shift and curtailment of early-stage development efforts.
• Customers of Day Three Labs may benefit from the company's focus on pharmaceutical-grade technology and innovation.
• Tenants of the company's real estate holdings may be affected by changes in the company's strategy.

Next Steps

• The company will seek approvals from both Rafael and Cyclo stockholders for the planned merger.
• The company will work towards the effectiveness of a registration statement on Form S-4 to register the shares of Rafael Class B Common Stock to be issued in the merger.
• The company will fund Cyclo's Phase III clinical trial for Trappsol Cyclo to its interim analysis in mid-2025.
• The company will make a determination as to whether or not to file an NDA for Trappsol Cyclo after the interim analysis.

Key Dates

Keywords

Cyclo Therapeutics, Trappsol Cyclo, LipoMedix, Cornerstone Pharmaceuticals, Rafael Medical Devices, Day Three Labs, Merger, Clinical Trials, Pharmaceuticals, Biotechnology, Medical Devices, Investment Portfolio, Real Estate